Breakthrough in Gene Editing: CRISPR-Based Epigenome Editing in Human Cells

Strategic Insights -

Recent advances in CRISPR technology have enabled the development of programmable tools to edit epigenetic modifications in human cells, potentially revolutionizing the treatment of diseases associated with aberrant epigenome patterning. Researchers at the University of California Berkeley have successfully demonstrated two methods to perform dCas9-mediated epigenome editing in human cell lines using plasmid DNA transfections and nucleofection of mRNAs encoding CRISPR epigenome editors. This breakthrough offers a safer alternative to traditional genome editing methods, as it does not require DNA breaks or changes in the human genome sequence.

Key Takeaways:

  • Researchers have developed a CRISPR-based epigenome editing tool that enables the precise rewriting of epigenetic modifications in human cells.
  • The tool, called CRISPR epigenome editing, uses catalytically dead Cas9 coupled with epigenetic modifiers to repress or activate targeted genes in mammalian genomes.
  • This method is safer than traditional genome editing as it does not require DNA breaks or changes in the human genome sequence.
  • The researchers demonstrated programmable epigenome editing to transiently repress genes using CRISPR interference (CRISPRi) and for silencing genes durably for many weeks using CRISPRoff.
  • Guidance is provided on quantitative methods to measure successful epigenome editing of target genes and key considerations on which epigenome editing tool to use, depending on experimental criteria.
  • The study highlights the potential of CRISPR-based epigenome editing in human cells for the treatment of diseases associated with aberrant epigenome patterning.
  • The research has been peer-reviewed and published in the Journal of Visualized Experiments.

Statistics:

  • 2 different methods are presented to perform dCas9-mediated epigenome editing in human cell lines.
  • Editing is achieved using plasmid DNA transfections and nucleofection of mRNAs encoding CRISPR epigenome editors.
  • CRISPR epigenome editing offers a safer alternative to traditional genome editing methods, as it does not require DNA breaks or changes in the human genome sequence.
  • The study demonstrates that CRISPR epigenome editing can be used to transiently repress genes using CRISPRi and for silencing genes durably for many weeks using CRISPRoff.
  • Researchers identified 4 key considerations on which epigenome editing tool to use, depending on experimental criteria.

Sources:

  • Crispr Epigenome Editing In Human Cells Using Plasmid Dna Transfection and Mrna Nucleofection Delivery. Journal of Visualized Experiments, 2025(219).
  • Investigators from University of California Berkeley Target Gene Editing (Crispr Epigenome Editing In Human Cells Using Plasmid Dna Transfection and Mrna Nucleofection Delivery). Biotech Week. July 9, 2025; p 261.